Comparative medical characteristics of ZDF-T2DM rats during the course of development to late stage disease

被引:7
|
作者
Pang, Yun-Li [1 ]
Hu, Jing-Wen [1 ]
Liu, Guang-Long [1 ]
Lu, Shuai-Yao [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China
[2] Yunnan Key Lab Vaccine Res Dev Severe Infect Dis, Kunming, Yunnan, Peoples R China
基金
中国国家自然科学基金;
关键词
clinical indicators; histopathology; molecular expression; type 2 diabetes mellitus; Zucker diabetic fatty rats;
D O I
10.1002/ame2.12030
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: There are few reports on the comparative medical characteristics of type 2 diabetes models in late stage. An analysis of comparative medical characteristics of Zucker diabetic fatty type 2 diabetes mellitus (ZDF-T2DM) rats during the course of development to late stage disease was performed. Methods: In this study, ZDF rats were fed with high-sugar and high-fat diets to raise the fasting blood glucose, and develop of type 2 diabetes. At the late stage of T2DM, the preliminary comparative medical characteristics of the T2DM model were analyzed through the detection of clinical indicators, histopathology, related cytokine levels, and insulin-related signaling molecule expression levels. Results: In the T2DM group, the fasting blood glucose was higher than 6.8 mmol/L, the serum insulin, leptin, and adiponectin levels were significantly decreased, and glucose intolerance and insulin resistance were measured as clinical indicators. Regarding pathological indicators, a large number of pancreatic islet cells showed the reduction of insulin secretion, resulting in damaged glycogen synthesis and liver steatosis. At the molecular level, the insulin signal transduction pathway was inhibited by decreasing the insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2), phosphatidylinositol 3 kinase (PI3K), and glycogen synthesis kinase 3 beta (GSK-3 beta) expression levels. Conclusion: The results show that the ZDF/T2DM rats have typical clinical, histopathological, and molecular characteristics of human T2DM and thus can be used as an effective model for T2DM drug development and treatment of advanced T2DM.
引用
收藏
页码:203 / 211
页数:9
相关论文
共 6 条
  • [1] Comparative medical characteristics of ZDF-T2DM rats during the course of development to late stage disease
    Yun-Li Pang
    Jing-Wen Hu
    Guang-Long Liu
    Shuai-Yao Lu
    Animal Models and Experimental Medicine, 2018, 1 (03) : 203 - 211
  • [2] Metalloproteins and apolipoprotein C: candidate plasma biomarkers of T2DM screened by comparative proteomics and lipidomics in ZDF rats
    Wang, Shuai
    Lu, Zhiyuan
    Wang, Yuxin
    Zhang, Tianran
    He, Xiaodong
    NUTRITION & METABOLISM, 2020, 17 (01)
  • [3] Metalloproteins and apolipoprotein C: candidate plasma biomarkers of T2DM screened by comparative proteomics and lipidomics in ZDF rats
    Shuai Wang
    Zhiyuan Lu
    Yuxin Wang
    Tianran Zhang
    Xiaodong He
    Nutrition & Metabolism, 17
  • [4] Carob-Fruit-Enriched Meat Ameliorates Non-Alcoholic Steatohepatitis In Late-Stage T2DM Rats
    Macho-Gonzalez, A.
    Garcimartin, A.
    Lopez-Oliva, M. E.
    Garcia-Fernandez, R.
    Hernandez-Martin, M.
    Redondo-Castillejo, R.
    Parfenova, A.
    Bocanegra, A.
    Bastida, S.
    Benedi, J.
    Sanchez-Muniz, F. J.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 116 : 61 - 62
  • [5] The preventive and therapeutic consumption of meat enriched with carob fruit extract, rich in phenolic compounds, improves colonic antioxidant status in late-stage T2DM rats
    Macho-Gonzalez, Adrian
    Ticona, Luis Apaza
    Redondo-Castillejo, Rocio
    Hernandez-Martin, Marina
    Sanchez-Muniz, Francisco Jose
    Hernaiz, Maria Jose
    Bastida, Sara
    Benedi, Juana
    Bocanegra, Aranzazu
    Lopez-Oliva, Maria Elvira
    Mateos-Vega, Carmen
    Garcimartin, Alba
    FOOD CHEMISTRY, 2024, 450
  • [6] Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) who progressed to stage 3A chronic kidney disease during treatment
    Roussel, R.
    de Zeeuw, D.
    Law, G.
    Meininger, G.
    DIABETOLOGIA, 2014, 57 : S322 - S323